Comparisons

IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a rare flat-rate model — your price never increases as your dose goes up. We reviewed their pricing, clinical oversight, and transparency. Key finding: the flat-rate pricing is genuinely valuable, but IvyRx doesn't publicly disclose a named medical director or their compounding pharmacy partners, which are meaningful gaps for patients who want to verify clinical quality.

Updated May 18, 2026 with Week 5 IQVIA data: 10,248 weekly Rx (+40% week-over-week re-acceleration). Oral Wegovy produces 16.6% body weight loss vs Foundayo's 12.4%, but Foundayo starts at $149/mo self-pay (WAC $649/mo) vs Wegovy's $1,349/mo and has no fasting requirement. PBM formulary activation expected to drive Week 6 acceleration. Full comparison with OASIS and ATTAIN trial data.

Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo — a program Mounjaro does not offer.

Verified April 2026: Zepbound (tirzepatide) produces 20.9% body weight loss vs Wegovy's (semaglutide) 14.9% per the SURMOUNT-1 and STEP-1 trials. Wegovy self-pay: $349/mo (NovoCare). Zepbound self-pay: $299-$449/mo (LillyDirect). Both $25/mo with commercial insurance + savings card.

Verified April 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,028/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). Both drop to $349/mo self-pay via NovoCare.

Verified April 2026: Oral Wegovy (25mg daily pill) produces 16.6% weight loss per the OASIS trial vs 14.9% for injectable Wegovy (2.4mg weekly) per STEP-1. Pill costs $1,349/mo list vs $349/mo self-pay for the injection through NovoCare. Full head-to-head comparison.

Verified April 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the head-to-head SURMOUNT-5 trial (NEJM). Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Tirzepatide costs $449/mo vs $349/mo self-pay. Full comparison.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.